An emerging role for cytopathology in precision oncology. Issue 3 (7th December 2015)

• Record Type: Journal Article
• Authors: Pauli, Chantal; Puca, Loredana; Mosquera, Juan Miguel; Robinson, Brian D.; Beltran, Himisha; Rubin, Mark A.; Rao, Rema A.
• Is Part Of: Cancer cytopathology. Volume 124:Issue 3(2016)
• Page Start: 167
• Page End: 173
• Publication Date: 2015-12-07
• Subjects: 3‐dimensional (3D) tumor organoid -- cytology -- cytology smear -- in vitro models -- next‐generation sequencing -- organoids -- precision medicine; Cancer -- Cytopathology -- Periodicals; Pathology, Cellular -- Periodicals; Cytology -- Technique -- Periodicals; 611.01815
• DOI: 10.1002/cncy.21647
• Languages: English
• ISSNs: 1934-662X

Abstract

Abstract : Precision medicine is an emerging field in medicine for disease prevention and treatment that takes into account the individual variability in genes, environment, and lifestyle for each individual patient. The authors have developed a special program as part of the Englander Institute for Precision Medicine to grow patient‐derived, 3‐dimensional tumor organoids for tumor‐specific drug testing, tailoring treatment strategies, and as models for studying drug resistance. Routine cytology preparations represent a cost‐effective and powerful tool to aid in performing molecular testing in the age of personalized medicine. In this commentary, the platforms used for the characterization and validation of patient‐derived, 3‐dimensional tumor organoids are outlined and discussed, and the role of cytology as a cost‐effective and powerful quality‐control measure is illustrated. Cancer Cytopathol 2016;124:167–173. © 2015 American Cancer Society . Abstract : Investigators at the Institute for Precision Medicine at Weill Cornell Medical College and New York‐Presbyterian Hospital have developed a special program to grow patient‐derived, 3‐dimensional tumor organoids that can be used for targeted and high‐throughput drug testing, tailoring standard‐of‐care treatment strategies, and as models to study drug resistance. Platforms for the characterization and validation of patient‐derived 3‐dimensional tumor organoids are described, and the role of cytology as a cost‐effective and powerful quality‐control measure is illustrated.